SPONSOR

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Total Trials

Recruiting

Phases

Phase 1, EARLY_Phase 1, Phase 2

Conditions studied: Relapsed/Refractory B-cell Malignancies Rheumatoid Arthritis (RA)Advanced Malignancies Acute Myeloid Leukemia Pneumonia; Pulmonary Infection Metastatic Non-small Cell Lung Cancer Urinary System Carcinoma Cirrhosis Decompensation Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is a clinical research sponsor with 22 registered studies on ClinicalTrials.gov, of which 22 are actively recruiting participants. Research covers conditions including Relapsed/Refractory B-cell Malignancies, Rheumatoid Arthritis (RA), Advanced Malignancies, Acute Myeloid Leukemia.

The trial portfolio spans Phase 1, EARLY_Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

How many clinical trials has Union Hospital, Tongji Medical College, Huazhong University of Science and Technology sponsored?

ClinicalMetric currently tracks 22 clinical trials sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, of which 22 are actively recruiting participants. These trials cover conditions including Relapsed/Refractory B-cell Malignancies, Rheumatoid Arthritis (RA), Advanced Malignancies. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Union Hospital, Tongji Medical College, Huazhong University of Science and Technology research focus on?

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology clinical trials span Relapsed/Refractory B-cell Malignancies, Rheumatoid Arthritis (RA), Advanced Malignancies, Acute Myeloid Leukemia, Pneumonia; Pulmonary Infection, and additional conditions. The research pipeline includes Phase 1, EARLY_Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Union Hospital, Tongji Medical College, Huazhong University of Science and Technology clinical trial?

To participate in a Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials with current recruitment status updated daily.

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Frequently Asked Questions — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Clinical Trials by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

Clinical Study of (A-319) in the Treatment of Active Rheumatoid Arthritis

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

A Multicenter Randomized Trial of CT-Based AI Decision Support for Early Pneumonia Care

Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer

The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors

The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis

Assessment of the Predictive Value of Anti-beta1AR and Anti-L-CaC Antibodies in the Evolution to Dilated Cardiomyopathy in Patients With Acute Viral Myocarditis

Using Artificial Intelligence to Improve Radiologists' Performance in Radiology Report Writing: a Randomised Controlled Trial

Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer

Fecal Microbiota Transplantation for the Treatment of ICU Delirium

Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC

Metabolic and Functional Study of γδ T Cells in Critically Ill Patients

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

A Study of YKST02 in Participants With Primary IgA Nephropathy

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

TIPS With or Without BCAA